- Home
- CHEB vs IRWD Comparison
CHEB vs IRWD Comparison
Compare CHEB & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHEB
- IRWD
- Stock Information
- Founded
- CHEB 2024
- IRWD 1998
- Country
- CHEB Singapore
- IRWD United States
- Employees
- CHEB N/A
- IRWD N/A
- Industry
- CHEB
- IRWD Biotechnology: Pharmaceutical Preparations
- Sector
- CHEB
- IRWD Health Care
- Exchange
- CHEB NYSE
- IRWD Nasdaq
- Market Cap
- CHEB 122.8M
- IRWD 124.0M
- IPO Year
- CHEB 2024
- IRWD 2010
- Fundamental
- Price
- CHEB $10.03
- IRWD $0.75
- Analyst Decision
- CHEB
- IRWD Buy
- Analyst Count
- CHEB 0
- IRWD 5
- Target Price
- CHEB N/A
- IRWD $4.94
- AVG Volume (30 Days)
- CHEB 91.4K
- IRWD 1.8M
- Earning Date
- CHEB 01-01-0001
- IRWD 08-07-2025
- Dividend Yield
- CHEB N/A
- IRWD N/A
- EPS Growth
- CHEB N/A
- IRWD N/A
- EPS
- CHEB N/A
- IRWD N/A
- Revenue
- CHEB N/A
- IRWD $317,676,000.00
- Revenue This Year
- CHEB N/A
- IRWD N/A
- Revenue Next Year
- CHEB N/A
- IRWD N/A
- P/E Ratio
- CHEB N/A
- IRWD N/A
- Revenue Growth
- CHEB N/A
- IRWD N/A
- 52 Week Low
- CHEB $6.09
- IRWD $0.53
- 52 Week High
- CHEB $14.31
- IRWD $7.11
- Technical
- Relative Strength Index (RSI)
- CHEB N/A
- IRWD 54.95
- Support Level
- CHEB N/A
- IRWD $0.70
- Resistance Level
- CHEB N/A
- IRWD $0.77
- Average True Range (ATR)
- CHEB 0.00
- IRWD 0.06
- MACD
- CHEB 0.00
- IRWD 0.01
- Stochastic Oscillator
- CHEB 0.00
- IRWD 72.44
About CHEB CHENGHE ACQUISITION II CO
Chenghe Acquisition II Co is a blank check company.
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.